Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Rare Kidney Diseases Market Expected to Be in 2029?

The market for rare kidney diseases has seen significant growth in recent years. There is projected to be an increase from $2.76 billion in 2024 to $3.03 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. Factors contributing to the growth during the historic period include heightened identification of the disease, designation of orphan drugs, advancements in patient advocacy and awareness, and global collaboration in research.

In the incoming years, a substantial increase in the market size of rare kidney diseases is anticipated. The value is projected to reach “$4.41 billion by 2029, expanding at a compound annual growth rate (CAGR) of 9.8%“. Factors contributing to this growth in the predicted timeframe include the advent of gene therapies, a rise in funding for research into rare diseases, collaborations among key players, and worldwide efforts to tackle rare diseases. Key trends to watch during this period entail a focus on patient needs, utilisation of real-world data and analytics, advancements in regulations, the use of telemedicine and remote supervision, as well as worldwide health initiatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

What Are The Contributors To Demand In The Rare Kidney Diseases Market?

The rare kidney disease market is poised for significant growth, catalyzed by government initiatives and funding focused on kidney disorders. Defined as a form of financial support offered by the government to entities whose ideas or projects can ameliorate public services and bolster the economy, these initiatives are playing a key role in enhancing disease surveillance and bettering the lives of people affected by various kidney diseases. They hinge upon an extensive public health strategy that draws in other public health agencies and national entities. To illustrate, in July 2022, the United States House Committee on Appropriations of the House of Representatives launched several investment schemes aimed at enhancing kidney health. These included allocating $8.5 million to the Centers for Disease Control and Prevention’s (CDC) chronic kidney disease program, a move designed to bolster activities fostering regular kidney disease awareness, diagnosis, and treatment. Additionally, the National Living Donor Assistance Center received a further $1 million investment aimed at bolstering living donations, making a total of $8 million dedicated to ongoing innovation and research. Consequently, such government backing targeted at kidney disorders is playing a crucial role in propelling the rare kidney disease market.

The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type Of Molecule: Small Molecules, Biologics

3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management

2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics

3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents

4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies

5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies

6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

What Future Market Trends Are Projected For The Rare Kidney Diseases Industry?

The increasing focus on product innovation is a significant trend in the rare kidney disease market. By introducing new and creative product lines, key market players are aiming to solidify their market presence. In an exemplary move in September 2022, STADA Arzneimittel AG, a company based in Germany and specializing in generics, specialty pharma, and over-the-counter consumer health products, launched Kinpeygo (budesonide). This is the first medication endorsed by the EU for the treatment of a rare kidney disease, known as immunoglobulin A nephropathy (IgAN). The reformulated budesonide capsules represent the first and only approved treatment for primary IgAN in the EU. This is a rare, progressive, autoimmune kidney disease that is significantly under-treated, with a staggering 25%-30% of patients eventually requiring dialysis or kidney transplantation due to terminal kidney failure.

Who Are The Top-Ranked Companies In The Rare Kidney Diseases Market Today?

Major companies operating in the rare kidney diseases market include Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc., Savara Inc.

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

How Is Rare Kidney Diseases Market Adoption Varying Across Different Regions And Sectors?

North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11908&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model